UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
发明人:
CHOI, HO YOUNG,최호영,HAM, IN HYE,함인혜,YANG, GAB SIK,양갑식,LEE, KYUNG JIN,이경진,LEE, MI HWA,이미화
申请号：
KR1020120005711
公开号：
KR1020130084827A
申请日:
2012.01.18
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: A pharmaceutical composition for preventing and treating inflammation, sepsis, or septic shock is provided to reduce the expression of inflammatory factors by treating with prunetin and to improve survival rates of prunetin-pretreated animals when the animals is treated with LPS.CONSTITUTION: A pharmaceutical composition for preventing and treating inflammation, sepsis, or septic shock contains prunetin or a pharmaceutically acceptable salt thereof as an active ingredient. The dosage of prunetin or the pharmaceutically acceptable salt is 1-15 mg per body weight of an individual. A composition for health foods for preventing and treating inflammation, sepsis, or septic shock contains prunetin or the pharmaceutically acceptable salt as an active ingredient. A cosmetic composition for preventing and treating inflammation, sepsis, or septic shock contains prunetin or the pharmaceutically acceptable salt as an active ingredient.COPYRIGHT KIPO 2013본 발명은 프루네틴을 유효성분으로 함유하는 염증, 패혈증 또는 패혈성 쇼크의 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로, 프루네틴의 처리에 의해 염증 관련 인자인 산화질소, iNOS, COX-2, IL-6 및 IL-1β의 발현 감소를 확인하였고, 또한, 프루네틴을 전처리한 동물에 LPS를 처리하여 패혈증을 유도하였을 때, 프루네틴을 전처리하지 않은 대조군 동물에 비해 생존률이 크게 개선된 것을 확인하였으므로, 이를 염증, 패혈증 또는 패혈성 쇼크의 치료용 약학적 조성물의 유효성분으로 사용할 수 있다.
